<![CDATA[Background: Erlotinib's effect on the skin is greatly recognized to cause rashes. To treat the rashes effectively, it is necessary to understand the mechanism of rashes formation induced by the drug. However, the mechanism underlying the effect was not well-known. Objective: This study measured the CINC1 and TTP mRNAs’ expression to elaborate the mechanism. Methods: An experimental preclinical quantitative study was designed. Rats were divided into three groups: placebo, low dose, and high dose based on the involvement and dosage of erlotinib, and were treated for 7 days. The samples were collected from the blood on days 0 and 7 and the skin on day 7. The blood was used to measure the circulating concentration of CINC-1, whereas the skin was used to measure the tissue expression of CINC1 and TTP mRNAs. Results: At mild rashes, the tissue expression of CINC1 and TTP mRNAs tended to elevate compared to the placebo, while at severe rashes, the TTP mRNA was suppressed in contrast to the CINC1 mRNA. The level of circulating CINC1 among the three groups following 7 days of treatment tended to elevate. Conclusion: The results suggest the involvement of CINC1 and TTP during the formation of erlotinib-induced rashes and the mechanism underlying the rashes formation was proposed accordingly. Furthermore, targeting these proteins could be a reference for a clinical study on the treatment of erlotinib-induced rashes.]]>
Copyrights © 2025
